142 related articles for article (PubMed ID: 35921900)
1. Dipeptidyl Peptidase 4 Inhibitor‒Associated Bullous Pemphigoid Is Characterized by an Altered Expression of Cytokines in the Skin.
Tuusa J; Kokkonen N; Mattila A; Huilaja L; Varpuluoma O; Rannikko S; Glumoff V; Miettunen J; Tasanen K
J Invest Dermatol; 2023 Jan; 143(1):78-86.e12. PubMed ID: 35921900
[TBL] [Abstract][Full Text] [Related]
2. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Mai Y; Nishie W; Izumi K; Shimizu H
Front Immunol; 2019; 10():1224. PubMed ID: 31191560
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
Nishie W
Immunol Med; 2019 Mar; 42(1):22-28. PubMed ID: 31169082
[TBL] [Abstract][Full Text] [Related]
4. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
[TBL] [Abstract][Full Text] [Related]
5. Analysis of IL-10 and IL-35 in dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
Kokubu H; Takahashi T; Kabuto M; Kouzaki H; Fujimoto N
Exp Dermatol; 2023 Sep; 32(9):1569-1574. PubMed ID: 37424368
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
Kawaguchi Y; Shimauchi R; Nishibori N; Kawashima K; Oshitani S; Fujiya A; Shibata T; Ohashi N; Izumi K; Nishie W; Shimizu H; Arima H; Sobajima H
J Diabetes Investig; 2019 Mar; 10(2):392-398. PubMed ID: 29920976
[TBL] [Abstract][Full Text] [Related]
7. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
Front Immunol; 2018; 9():542. PubMed ID: 29706950
[TBL] [Abstract][Full Text] [Related]
8. A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
Sawada K; Sawada T; Kobayashi T; Fujiki A; Matsushita T; Kawara S; Izumi K; Nishie W; Shimizu H; Takehara K; Hamaguchi Y
Immunol Med; 2021 Mar; 44(1):53-55. PubMed ID: 32634333
[TBL] [Abstract][Full Text] [Related]
9. Defining dipeptidyl peptidase-4 inhibitors-related bullous pemphigoid: A single-centre retrospective study.
Nieto-Benito LM; Bergón-Sendín M; Pulido-Pérez A; Rosell-Díaz ÁM; Parra-Blanco V; Suárez-Fernández R
Exp Dermatol; 2021 Sep; 30(9):1345-1351. PubMed ID: 34028898
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
Tasanen K; Varpuluoma O; Nishie W
Front Immunol; 2019; 10():1238. PubMed ID: 31275298
[TBL] [Abstract][Full Text] [Related]
11. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
[TBL] [Abstract][Full Text] [Related]
12. The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study.
Bukvić Mokos Z; Petković M; Balić A; Marinović B
Croat Med J; 2020 Apr; 61(2):93-99. PubMed ID: 32378375
[TBL] [Abstract][Full Text] [Related]
13. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
[TBL] [Abstract][Full Text] [Related]
14. Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.
Nätynki A; Leisti P; Tuusa J; Varpuluoma O; Huilaja L; Izumi K; Herukka SK; Ukkola O; Junttila J; Kokkonen N; Tasanen K
Front Immunol; 2022; 13():942131. PubMed ID: 35958564
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis.
Maki N; Nishie W; Takazawa M; Kakurai M; Yamada T; Umemoto N; Kawase M; Izumi K; Shimizu H; Demitsu T
J Dermatol; 2018 May; 45(5):600-602. PubMed ID: 29446164
[TBL] [Abstract][Full Text] [Related]
16. Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.
Mai Y; Nishie W; Izumi K; Yoshimoto N; Morita Y; Watanabe M; Toyonaga E; Ujiie H; Iwata H; Fujita Y; Nomura T; Sato-Matsumura KC; Shimizu S; Shimizu H
Br J Dermatol; 2018 Sep; 179(3):790-791. PubMed ID: 29624639
[No Abstract] [Full Text] [Related]
17. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
Nakama K; Koga H; Ishii N; Ohata C; Hashimoto T; Nakama T
JAMA Dermatol; 2018 Mar; 154(3):347-350. PubMed ID: 29299596
[TBL] [Abstract][Full Text] [Related]
18. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
Izumi K; Nishie W; Beniko M; Shimizu H
Front Immunol; 2019; 10():1439. PubMed ID: 31297116
[No Abstract] [Full Text] [Related]
19. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
Sun L; Wang C; Wu C; Zhou Y; Wang C
Ann Pharmacother; 2022 Feb; 56(2):205-212. PubMed ID: 34105395
[TBL] [Abstract][Full Text] [Related]
20. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.
Wu CY; Wu CY; Li CP; Chou YJ; Lin YH; Chang YT
Diabetes Res Clin Pract; 2021 Jan; 171():108546. PubMed ID: 33232759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
